Selectin-Dependent Organ Invasion and Prognostic Impact of Loss of CD2 in Systemic Mastocytosis
This study demonstrates that the loss of CD2 expression in systemic mastocytosis promotes a diffuse, leukemic organ invasion mediated by E- and P-selectins, leading to significantly reduced patient survival compared to CD2-positive disease.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside the human body, a specific type of white blood cell called a mast cell plays a vital role in how the immune system reacts to threats. In a condition known as systemic mastocytosis, these cells grow out of control, multiplying and gathering in organs like the bone marrow, skin, and digestive tract. For many patients, this disease remains manageable, with the rogue cells staying in tight, organized groups. However, for others, the disease becomes aggressive and dangerous. In these severe cases, the cells break free from their clusters, spreading widely through the body in a diffuse, chaotic manner that resembles leukemia. Understanding why some cells stay put while others scatter is crucial, because this shift from a contained state to a spreading one determines how long a patient survives.
Scientists have long suspected that the surface of these cells holds the key to their behavior. Specifically, they looked at a protein called CD2, which acts like a molecular glue. In healthy immune cells, this protein helps them stick together or to other surfaces. In the early, less dangerous stages of mastocytosis, the cancerous mast cells usually carry this protein on their surface. But as the disease worsens and becomes aggressive, these cells often lose the CD2 protein entirely. The big question was whether this loss was just a side effect of the disease getting worse, or if the disappearance of the protein actually caused the cells to scatter and invade new organs.
To find the answer, researchers at the Medical University of Vienna and their colleagues in Germany set up a series of experiments using human mast cells and mice. They started with a line of human mast cells that naturally contained a mix of two types: some that still had the CD2 protein and some that had lost it. The team carefully separated these cells into two distinct groups—one group that kept the protein and another that did not. They then injected these cells into the bellies of mice that had been bred to lack a working immune system, allowing the human cells to grow without being attacked.
The results were striking. The mice that received the cells with the CD2 protein developed small, contained clusters of mast cells in their lungs and other tissues. The cells seemed to stay together, forming distinct lumps rather than spreading everywhere. In contrast, the mice injected with the cells that had lost the CD2 protein showed a very different pattern. Instead of forming neat clusters, these cells spread out diffusely, infiltrating the organs in a loose, widespread manner. This difference in behavior had a direct impact on the mice's lives. The animals with the scattered, CD2-negative cells died much sooner, with a median survival of just 69 days, compared to 85 days for those with the CD2-positive cells. The loss of the protein appeared to turn a contained problem into a rapidly spreading one.
The researchers then wanted to understand how these cells managed to invade the organs in the first place. They suspected that the cells were using specific "docking" proteins on blood vessel walls to grab hold and move into the tissue. To test this, they used a special group of mice that lacked two specific docking proteins called E-selectin and P-selectin. When they injected the human mast cells into these mice, the cells could not invade the organs effectively. Whether the cells had the CD2 protein or not, they simply could not get into the lung tissue or spread through the body without those selectin docking points. This proved that the invasion process relies heavily on these selectin molecules, acting as the necessary bridge for the cells to cross from the blood into the organs.
To see if these findings applied to real people, the team looked back at medical records of 113 patients with systemic mastocytosis. They checked whether the patients' mast cells had the CD2 protein and tracked how long the patients lived. The data matched the mouse experiments perfectly. Patients whose mast cells still had the CD2 protein lived longer and had a better outlook than those whose cells had lost it. Furthermore, the loss of CD2 was much more common in patients with the advanced, aggressive forms of the disease. The study suggests that when these cancer cells lose the CD2 protein, they lose their ability to stick together, which allows them to break free and spread widely, leading to a more severe disease course.
The research also looked at the genetic makeup of the cells to see if losing CD2 triggered other changes. While the cells did show some differences in the genes they turned on, the most significant factor driving the change in behavior was the loss of CD2 itself. The cells without CD2 behaved more like circulating cancer cells, ready to detach and travel, while those with CD2 acted more like stationary tissue residents. This discovery highlights a specific molecular switch that controls whether the disease stays contained or becomes a widespread threat. By identifying that the loss of CD2 is a critical step in the progression of the disease, the study provides a clearer picture of why some patients fare worse than others and points to the importance of adhesion molecules in how cancer cells move through the body.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.